blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3303394

EP3303394 - ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.02.2021
Database last updated on 14.09.2024
FormerThe patent has been granted
Status updated on  06.03.2020
FormerGrant of patent is intended
Status updated on  30.10.2019
FormerExamination is in progress
Status updated on  11.01.2019
FormerRequest for examination was made
Status updated on  09.03.2018
FormerThe international publication has been made
Status updated on  09.12.2016
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): TR		published on 16.10.2024 [2024/42]
Applicant(s)For all designated states
Agenus Inc.
3 Forbes Road
Lexington, MA 02421 / US
For all designated states
Ludwig Institute for Cancer Research Ltd
Stadelhoferstrasse 22
8001 Zürich / CH
For all designated states
Memorial Sloan Kettering Cancer Center
1275 York Avenue
New York, NY 10065 / US
[2018/15]
Inventor(s)01 / van DIJK, Marc
Gaailaan 16
3722ZH Bilthoven / NL
02 / MUNDT, Cornelia, Anne
Hangstrasse 34
79539 Loerrach / DE
03 / RITTER, Gerd
Ludwig Institute For Cancer Research
666 Third Avenue 28th Floor
New York, NY 10017 / US
04 / SCHAER, David
715 Shore Acres Drive
Mamaroneck, NY 10543 / US
05 / WOLCHOK, Jedd, David
333 E30th Street Apt 17c
New York, NY 10016 / US
06 / MERGHOUB, Taha
10 Huron Avenue Apt 14k
Jersey City, NJ 07306 / US
07 / SAVITSKY, David, Adam
28 Sunrise Road
Boxford, MA 01921 / US
08 / FINDEIS, Mark, Arthur
431 School Street
Belmont, MA 02478 / US
09 / WILSON, Nicholas, Stuart
68 Electric Avenue Apartment 1
Somerville, MA 02144 / US
 [2018/15]
Representative(s)Lahrtz, Fritz, et al
Patentanwälte
Isenbruck Bösl Hörschler PartG mbB
Seckenheimer Landstr. 4
68163 Mannheim / DE
[N/P]
Former [2020/15]Lahrtz, Fritz
Patentanwälte
Isenbruck Bösl Hörschler PartG mbB
Prinzregentenstraße 68
81675 München / DE
Former [2018/15]Lahrtz, Fritz
Isenbruck Bösl Hörschler LLP Patentanwälte Prinzregentenstrasse 68
81675 München / DE
Application number, filing date16728509.727.05.2016
[2018/15]
WO2016US34508
Priority number, dateUS201562168391P29.05.2015         Original published format: US 201562168391 P
US201562182363P19.06.2015         Original published format: US 201562182363 P
US201562190653P09.07.2015         Original published format: US 201562190653 P
US201562257202P18.11.2015         Original published format: US 201562257202 P
US201662280263P19.01.2016         Original published format: US 201662280263 P
US201662292500P08.02.2016         Original published format: US 201662292500 P
US201662294558P12.02.2016         Original published format: US 201662294558 P
US201662323226P15.04.2016         Original published format: US 201662323226 P
[2018/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016196237
Date:08.12.2016
Language:EN
[2016/49]
Type: A1 Application with search report 
No.:EP3303394
Date:11.04.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 08.12.2016 takes the place of the publication of the European patent application.
[2018/15]
Type: B1 Patent specification 
No.:EP3303394
Date:08.04.2020
Language:EN
[2020/15]
Search report(s)International search report - published on:EP08.12.2016
ClassificationIPC:C07K16/28
[2018/15]
CPC:
C07K16/2818 (EP,CN,IL,KR,US); A61K31/47 (CN); A61K31/7068 (CN);
A61K39/395 (KR); A61K39/3955 (CN); A61K45/06 (CN);
A61K47/6803 (KR); A61K47/6849 (EP,IL,KR,US); A61K51/1027 (IL,KR,US);
A61P31/00 (EP,CN,IL); A61P35/00 (EP,CN,IL,US); A61P37/04 (EP,IL,US);
C07K16/283 (IL,KR,US); C12N15/85 (CN); C12N5/0682 (CN);
A61K2039/505 (EP,CN,IL,KR,US); A61K2039/507 (CN); C07K2317/21 (EP,IL,US);
C07K2317/33 (EP,IL,KR,US); C07K2317/34 (EP,IL,KR,US); C07K2317/41 (IL,KR,US);
C07K2317/51 (CN); C07K2317/515 (CN); C07K2317/52 (EP,CN,IL,US);
C07K2317/56 (CN,IL,US); C07K2317/565 (CN,IL,US); C07K2317/567 (IL,US);
C07K2317/73 (EP,IL,KR,US); C07K2317/76 (EP,IL,KR,US); C07K2317/92 (EP,IL,US);
C12N2510/00 (CN) (-)
C-Set:
A61K31/47, A61K2300/00 (CN);
A61K31/7068, A61K2300/00 (CN);
A61K39/3955, A61K2300/00 (CN)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/15]
Extension statesBA21.12.2017
ME21.12.2017
Validation statesMA28.02.2018
MD28.02.2018
TitleGerman:ANTI-CTLA-4-ANTIKÖRPER UND VERFAHREN ZUR VERWENDUNG DAVON[2018/15]
English:ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF[2018/15]
French:ANTICORPS ANTI-CTLA-4 ET MÉTHODES D'UTILISATION DE CEUX-CI[2018/15]
Entry into regional phase21.12.2017National basic fee paid 
21.12.2017Designation fee(s) paid 
21.12.2017Examination fee paid 
Examination procedure21.12.2017Examination requested  [2018/15]
21.12.2017Date on which the examining division has become responsible
02.11.2018Amendment by applicant (claims and/or description)
14.01.2019Despatch of a communication from the examining division (Time limit: M04)
17.04.2019Reply to a communication from the examining division
06.06.2019Despatch of a communication from the examining division (Time limit: M04)
31.07.2019Reply to a communication from the examining division
31.10.2019Communication of intention to grant the patent
25.02.2020Fee for grant paid
25.02.2020Fee for publishing/printing paid
25.02.2020Receipt of the translation of the claim(s)
Divisional application(s)EP20168222.6  / EP3736290
Opposition(s)12.01.2021No opposition filed within time limit [2021/11]
Fees paidRenewal fee
29.05.2018Renewal fee patent year 03
28.05.2019Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL08.04.2020
MC08.04.2020
RO08.04.2020
SM08.04.2020
CY27.05.2020
CZ27.05.2020
FI27.05.2020
HR27.05.2020
LT27.05.2020
LU27.05.2020
LV27.05.2020
PL27.05.2020
SK27.05.2020
TR27.05.2020
HU28.05.2020
SE28.05.2020
SI28.05.2020
BE31.05.2020
CH31.05.2020
EE31.05.2020
LI31.05.2020
NL01.06.2020
FR08.06.2020
GB08.07.2020
NO08.07.2020
DK31.07.2020
GR09.12.2020
[2024/42]
Former [2022/37]AL08.04.2020
MC08.04.2020
RO08.04.2020
SM08.04.2020
CY27.05.2020
CZ27.05.2020
FI27.05.2020
HR27.05.2020
LT27.05.2020
LU27.05.2020
LV27.05.2020
PL27.05.2020
SK27.05.2020
HU28.05.2020
SE28.05.2020
SI28.05.2020
BE31.05.2020
CH31.05.2020
EE31.05.2020
LI31.05.2020
NL01.06.2020
FR08.06.2020
GB08.07.2020
NO08.07.2020
DK31.07.2020
GR09.12.2020
Former [2022/33]AL08.04.2020
MC08.04.2020
RO08.04.2020
SM08.04.2020
CY27.05.2020
CZ27.05.2020
FI27.05.2020
HR27.05.2020
LT27.05.2020
LU27.05.2020
LV27.05.2020
SK27.05.2020
HU28.05.2020
SE28.05.2020
SI28.05.2020
BE31.05.2020
CH31.05.2020
EE31.05.2020
LI31.05.2020
NL01.06.2020
FR08.06.2020
GB08.07.2020
NO08.07.2020
DK31.07.2020
GR09.12.2020
Former [2022/09]AL08.04.2020
MC08.04.2020
RO08.04.2020
SM08.04.2020
CY27.05.2020
CZ27.05.2020
HR27.05.2020
LT27.05.2020
LU27.05.2020
LV27.05.2020
SK27.05.2020
HU28.05.2020
SE28.05.2020
SI28.05.2020
BE31.05.2020
CH31.05.2020
EE31.05.2020
LI31.05.2020
NL01.06.2020
FR08.06.2020
GB08.07.2020
NO08.07.2020
DK31.07.2020
GR09.12.2020
Former [2022/07]AL08.04.2020
MC08.04.2020
RO08.04.2020
SM08.04.2020
CZ27.05.2020
HR27.05.2020
LT27.05.2020
LU27.05.2020
LV27.05.2020
SK27.05.2020
HU28.05.2020
SE28.05.2020
SI28.05.2020
BE31.05.2020
CH31.05.2020
EE31.05.2020
LI31.05.2020
NL01.06.2020
FR08.06.2020
GB08.07.2020
NO08.07.2020
DK31.07.2020
GR09.12.2020
Former [2021/50]AL08.04.2020
MC08.04.2020
RO08.04.2020
SM08.04.2020
CZ27.05.2020
HR27.05.2020
IE27.05.2020
LT27.05.2020
LU27.05.2020
LV27.05.2020
SK27.05.2020
HU28.05.2020
SE28.05.2020
SI28.05.2020
BE31.05.2020
CH31.05.2020
EE31.05.2020
LI31.05.2020
NL01.06.2020
FR08.06.2020
GB08.07.2020
NO08.07.2020
DK31.07.2020
GR09.12.2020
Former [2021/37]AL08.04.2020
MC08.04.2020
RO08.04.2020
SM08.04.2020
CZ27.05.2020
HR27.05.2020
IE27.05.2020
LT27.05.2020
LU27.05.2020
LV27.05.2020
SK27.05.2020
HU28.05.2020
SE28.05.2020
SI28.05.2020
BE31.05.2020
CH31.05.2020
EE31.05.2020
LI31.05.2020
NL01.06.2020
FR08.06.2020
GB08.07.2020
NO08.07.2020
DK31.07.2020
DE01.12.2020
GR09.12.2020
Former [2021/36]AL08.04.2020
MC08.04.2020
RO08.04.2020
SM08.04.2020
CZ27.05.2020
HR27.05.2020
IE27.05.2020
LT27.05.2020
LU27.05.2020
LV27.05.2020
SK27.05.2020
HU28.05.2020
SE28.05.2020
SI28.05.2020
BE31.05.2020
CH31.05.2020
EE31.05.2020
LI31.05.2020
NL01.06.2020
FR08.06.2020
GB08.07.2020
NO08.07.2020
DE01.12.2020
GR09.12.2020
Former [2021/28]AL08.04.2020
MC08.04.2020
RO08.04.2020
SM08.04.2020
CZ27.05.2020
HR27.05.2020
IE27.05.2020
LT27.05.2020
LU27.05.2020
LV27.05.2020
SK27.05.2020
HU28.05.2020
SE28.05.2020
BE31.05.2020
CH31.05.2020
EE31.05.2020
LI31.05.2020
NL01.06.2020
FR08.06.2020
GB08.07.2020
NO08.07.2020
DE01.12.2020
GR09.12.2020
Former [2021/25]AL08.04.2020
MC08.04.2020
RO08.04.2020
SM08.04.2020
CZ27.05.2020
IE27.05.2020
LT27.05.2020
LU27.05.2020
LV27.05.2020
HU28.05.2020
SE28.05.2020
BE31.05.2020
CH31.05.2020
EE31.05.2020
LI31.05.2020
NL01.06.2020
FR08.06.2020
GB08.07.2020
NO08.07.2020
DE01.12.2020
GR09.12.2020
Former [2021/24]AL08.04.2020
MC08.04.2020
RO08.04.2020
SM08.04.2020
CZ27.05.2020
IE27.05.2020
LT27.05.2020
LU27.05.2020
LV27.05.2020
HU28.05.2020
SE28.05.2020
BE31.05.2020
CH31.05.2020
EE31.05.2020
LI31.05.2020
NL01.06.2020
FR08.06.2020
GB08.07.2020
NO08.07.2020
GR09.12.2020
Former [2021/23]AL08.04.2020
MC08.04.2020
RO08.04.2020
SM08.04.2020
CZ27.05.2020
IE27.05.2020
LT27.05.2020
LU27.05.2020
LV27.05.2020
HU28.05.2020
SE28.05.2020
BE31.05.2020
CH31.05.2020
EE31.05.2020
LI31.05.2020
NL01.06.2020
FR08.06.2020
GB08.07.2020
NO08.07.2020
GR09.12.2020
Former [2021/22]AL08.04.2020
MC08.04.2020
RO08.04.2020
SM08.04.2020
CZ27.05.2020
IE27.05.2020
LT27.05.2020
LU27.05.2020
LV27.05.2020
HU28.05.2020
CH31.05.2020
EE31.05.2020
LI31.05.2020
NL01.06.2020
GB08.07.2020
NO08.07.2020
GR09.12.2020
Former [2021/20]AL08.04.2020
MC08.04.2020
RO08.04.2020
SM08.04.2020
CZ27.05.2020
IE27.05.2020
LT27.05.2020
LU27.05.2020
LV27.05.2020
HU28.05.2020
CH31.05.2020
EE31.05.2020
LI31.05.2020
NL01.06.2020
GR09.12.2020
Former [2021/15]AL08.04.2020
MC08.04.2020
RO08.04.2020
SM08.04.2020
CZ27.05.2020
LT27.05.2020
LU27.05.2020
LV27.05.2020
HU28.05.2020
CH31.05.2020
EE31.05.2020
LI31.05.2020
NL01.06.2020
GR09.12.2020
Former [2021/12]AL08.04.2020
MC08.04.2020
RO08.04.2020
SM08.04.2020
CZ27.05.2020
LT27.05.2020
LV27.05.2020
HU28.05.2020
CH31.05.2020
EE31.05.2020
LI31.05.2020
NL01.06.2020
GR09.12.2020
Former [2021/10]AL08.04.2020
MC08.04.2020
RO08.04.2020
SM08.04.2020
CZ27.05.2020
LT27.05.2020
LV27.05.2020
HU28.05.2020
CH31.05.2020
EE31.05.2020
LI31.05.2020
GR09.12.2020
Former [2021/09]AL08.04.2020
MC08.04.2020
RO08.04.2020
SM08.04.2020
CZ27.05.2020
LT27.05.2020
HU28.05.2020
CH31.05.2020
EE31.05.2020
LI31.05.2020
GR09.12.2020
Former [2021/08]AL08.04.2020
RO08.04.2020
SM08.04.2020
LT27.05.2020
HU28.05.2020
CH31.05.2020
LI31.05.2020
Former [2021/07]AL08.04.2020
LT27.05.2020
CH31.05.2020
LI31.05.2020
Former [2021/04]AL08.04.2020
Cited inInternational search[X]WO0243478  (MEDAREX INC [US], et al);
 [X]EP1262193  (PFIZER PROD INC [US]);
 [X]US2006240006  (CHU CHISHIH [TW], et al);
 [Y]WO2008100562  (MED COLLEGE GEORGIA RES INST [US], et al);
 [XY]WO2009100140  (MEDAREX INC [US], et al);
 [XY]WO2012120125  (ANTITOPE LTD [GB], et al);
 [Y]WO2012162277  (MERCK SHARP & DOHME [US], et al);
 [Y]WO2014144960  (ABBVIE BIOTHERAPEUTICS INC [US]);
by applicantUS4044126
 US4364923
 US4414209
 US4444887
 WO8605807
 US4716111
 WO8901036
 US4816567
 US4816397
 WO9002809
 WO9110737
 WO9110741
 WO9201047
 US5122464
 WO9218619
 WO9222324
 WO9311236
 US5223409
 WO9404678
 WO9425591
 US5403484
 US5413923
 WO9515982
 US5427908
 WO9520401
 US5516637
 US5545806
 US5569825
 WO9634096
 WO9633735
 US5571698
 US5580717
 WO9713844
 US5625126
 US5633425
 US5658727
 US5661016
 US5698426
 US5709874
 US5733743
 WO9816654
 US5750753
 US5759542
 WO9824893
 US5780225
 US5807715
 US5814318
 US5821047
 WO9846645
 WO9850433
 US5837242
 US5840674
 US5860957
 US5869620
 US5885793
 US5900252
 US5939598
 US5948433
 US5965726
 US5969108
 US5972366
 US5983134
 US5985317
 US5985307
 US5989830
 US6004534
 US6005079
 US6010715
 US6024975
 US6039975
 US6048736
 US6060082
 US6071495
 US6075181
 US6120751
 US6131570
 US6132992
 US6139865
 US6150184
 US6167301
 US6174666
 WO0144301
 US6256533
 US6253872
 US6261595
 US6267983
 US6271359
 US6274552
 US6291664
 US6316652
 US6331415
 US6414132
 US2004014194
 US6794498
 US7183076
 US7709226
 US7951917
 US8227577
 US8586713
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.